" class="no-js "lang="en-US"> Amyl Therapeutics - Pharmtech Focus
Tuesday, January 31, 2023
Amyl Therapeutics | Pharmtech Focus

Amyl Therapeutics

About Amyl Therapeutics

Amyl Therapeutics

Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis.

Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Related Story

Amyl Therapeutics Closes €18.3 million Series A Financing to Develop Novel Therapies for Amyloidosis

June 3 2021

Amyl Therapeutics (‘Amyl’), a preclinical stage biotechnology company developing its amyloid fibrils specific technology platform named […]